DTIL•benzinga•
Precision BioSciences Accelerates Development Of First-in-Class In Vivo Gene Editing Therapy PBGENE-DMD For Duchenne Muscular Dystrophy Targeting Exons 45–55 Hot Spot, IND/CTA Submission Planned For 2025 And Clinical Data Expected In 2026
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 14, 2025 by benzinga